Summary
Global Markets Direct’s, ‘Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review, 2016’, provides an overview of the Chugai Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Chugai Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Chugai Pharmaceutical Co., Ltd.
- The report provides overview of Chugai Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Chugai Pharmaceutical Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Chugai Pharmaceutical Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Chugai Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chugai Pharmaceutical Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chugai Pharmaceutical Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Chugai Pharmaceutical Co., Ltd. Snapshot 7
Chugai Pharmaceutical Co., Ltd. Overview 7
Key Information 7
Key Facts 7
Chugai Pharmaceutical Co., Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
Chugai Pharmaceutical Co., Ltd. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Chugai Pharmaceutical Co., Ltd. - Pipeline Products Glance 17
Chugai Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 17
Phase III Products/Combination Treatment Modalities 17
Chugai Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Chugai Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
Chugai Pharmaceutical Co., Ltd. - Drug Profiles 22
atezolizumab 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
bevacizumab 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
eldecalcitol 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
gantenerumab 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
lebrikizumab 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
obinutuzumab 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SA-237 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
tocilizumab 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
codrituzumab 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
nemolizumab 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
basmisanil 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
EOS-789 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
PCO-371 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
polatuzumab vedotin 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
RG-7304 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
taselisib 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
CH-5036249 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CH-5164840 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CH-5449302 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
CH-5451098 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CVE-199 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ERY-974 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
maxacalcitol 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
NA-255 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
gMSC-1 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Chugai Pharmaceutical Co., Ltd. - Pipeline Analysis 74
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Target 74
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 76
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 77
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 78
Chugai Pharmaceutical Co., Ltd. - Recent Pipeline Updates 80
Chugai Pharmaceutical Co., Ltd. - Dormant Projects 108
Chugai Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 109
Discontinued Pipeline Product Profiles 109
nitazoxanide 109
basimglurant 109
bevacizumab 110
hyaluronate sodium 110
NA-808 111
onartuzumab 111
orlistat 111
PA-799 111
parsatuzumab 111
pictilisib 111
RG-7167 112
sembragiline 112
tocilizumab 112
trastuzumab emtansine 112
Chugai Pharmaceutical Co., Ltd. - Company Statement 113
Chugai Pharmaceutical Co., Ltd. - Locations And Subsidiaries 115
Head Office 115
Other Locations & Subsidiaries 115
Appendix 118
Methodology 118
Coverage 118
Secondary Research 118
Primary Research 118
Expert Panel Validation 118
Contact Us 118
Disclaimer 119
List of Tables
Chugai Pharmaceutical Co., Ltd., Key Information 7
Chugai Pharmaceutical Co., Ltd., Key Facts 7
Chugai Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016 9
Chugai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016 11
Chugai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016 12
Chugai Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016 13
Chugai Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 14
Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016 15
Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016 16
Chugai Pharmaceutical Co., Ltd. - Phase III, 2016 17
Chugai Pharmaceutical Co., Ltd. - Phase II, 2016 18
Chugai Pharmaceutical Co., Ltd. - Phase I, 2016 19
Chugai Pharmaceutical Co., Ltd. - Preclinical, 2016 20
Chugai Pharmaceutical Co., Ltd. - Discovery, 2016 21
Chugai Pharmaceutical Co., Ltd. - Pipeline by Target, 2016 74
Chugai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016 76
Chugai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016 77
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 78
Chugai Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2016 80
Chugai Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016 108
Chugai Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016 109
Chugai Pharmaceutical Co., Ltd., Other Locations 115
Chugai Pharmaceutical Co., Ltd., Subsidiaries 116
List of Figures
Chugai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016 9
Chugai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016 11
Chugai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016 12
Chugai Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016 13
Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016 15
Chugai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2016 74
Chugai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016 76
Chugai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016 77
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016 78
